Farallon Capital Management LLC Exelixis, Inc. Transaction History

Farallon Capital Management LLC

$18.8 Billion
Q4 2024

A detailed history of Farallon Capital Management LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Farallon Capital Management LLC holds 23,439,500 shares of EXEL stock, worth $864 Million. This represents 4.16% of its overall portfolio holdings.

Number of Shares

23,439,500

Holding current value

$864 Million

% of portfolio

4.16%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$25.39 - $36.46 $50 Million - $71.9 Million	-1,971,000 Reduced 7.76%	23,439,500 $781 Million
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $37.2 Million - $46.7 Million	-1,692,000 Reduced 6.24%	25,410,500 $659 Million
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $8.62 Million - $10.1 Million	424,000 Added 1.59%	27,102,500 $609 Million
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $887,480 - $1.05 Million	44,000 Added 0.17%	26,678,500 $633 Million
Q4 2023 Feb 14, 2024	BUY	$19.25 - $24.13 $513 Million - $643 Million	26,634,500 New	26,634,500 $639 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $492 Million - $588 Million	25,860,000 New	25,860,000 $565 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $43.5 Million - $49 Million	2,394,000 Added 10.2%	25,860,000 $494 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $205 Million - $245 Million	12,597,851 Added 115.92%	23,466,000 $455 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $2.88 Million - $3.34 Million	192,305 Added 1.8%	10,868,149 $174 Million
Q3 2022 Nov 14, 2022	BUY	$15.68 - $22.27 $7.86 Million - $11.2 Million	501,571 Added 4.93%	10,675,844 $167 Million
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $6.03 Million - $8.01 Million	-345,788 Reduced 3.29%	10,174,273 $212 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $28.3 Million - $37.7 Million	1,660,904 Added 18.75%	10,520,061 $238 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $12.7 Million - $17.5 Million	-800,555 Reduced 8.29%	8,859,157 $162 Million
Q3 2021 Nov 15, 2021	SELL	$16.3 - $21.14 $21.8 Million - $28.3 Million	-1,340,288 Reduced 12.18%	9,659,712 $204 Million
Q2 2021 Aug 13, 2021	BUY	$17.95 - $25.56 $4.49 Million - $6.39 Million	250,000 Added 2.33%	11,000,000 $200 Million
Q1 2021 May 17, 2021	SELL	$20.53 - $25.22 $5.13 Million - $6.31 Million	-250,000 Reduced 2.27%	10,750,000 $243 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $4.6 Million - $6.2 Million	250,000 Added 2.33%	11,000,000 $221 Million
Q3 2020 Nov 16, 2020	BUY	$20.67 - $26.94 $10.3 Million - $13.5 Million	500,000 Added 4.88%	10,750,000 $263 Million
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $4.12 Million - $6.86 Million	250,000 Added 2.5%	10,250,000 $243 Million
Q1 2020 May 15, 2020	BUY	$14.46 - $21.8 $36.2 Million - $54.5 Million	2,500,000 Added 33.33%	10,000,000 $172 Million
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $87.1 Million - $109 Million	5,750,000 Added 328.57%	7,500,000 $132 Million
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $22.1 Million - $28.3 Million	-1,250,000 Reduced 41.67%	1,750,000 $30.9 Million
Q1 2019 May 15, 2019	BUY	$19.6 - $24.76 $19.6 Million - $24.8 Million	1,000,000 Added 50.0%	3,000,000 $71.4 Million
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $12.6 Million - $20.1 Million	920,000 Added 85.19%	2,000,000 $39.3 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $17.1 Million - $24.2 Million	1,080,000 New	1,080,000 $19.1 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $28.8 Million - $36.8 Million	-1,190,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $27.8 Million - $34.8 Million	1,190,000	1,190,000 $28.8 Million

Others Institutions Holding EXEL

# of Institutions

564

Shares Held

251M

Call Options Held

1.45M

Put Options Held

1.13M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.9B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.

Account

Farallon Capital Management LLC Exelixis, Inc. Transaction History